+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End Use, Region, with Growth Forecasts, 2025-2030- Product Image
Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End Use, Region, with Growth Forecasts, 2025-2030- Product Image
New

Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End Use, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5450236
Description Jump to:
The Neurological Biomarkers Market was valued at USD 9.1 Billion in 2024, and is projected to reach USD 18.75 Billion by 2030, rising at a CAGR of 12.90%. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights

  • In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson’s disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definition
1.1.1.1 Application Segment
1.1.1.2 Type Segment
1.1.1.3 End Use Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Application and Type Snapshot
2.3 End Use Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer’s Disease
3.3.2 Parkinson’s Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Prevalence of Neurological Diseases
3.4.1.2 Technological Advancements
3.4.1.3 Increased Funding For R&D in Biomarkers
3.4.2 Market Restraint Analysis
3.4.2.1 Lack of Consumer Awareness
3.4.2.2 Reimbursement Policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, by Type, 2018-2030 (USD Million)
4.1 Neurological Biomarkers Market: Type Movement Analysis
4.1.1 Genomic
4.1.1.1 Genomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.2 Proteomic
4.1.2.1 Proteomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.3 Metabolomic
4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.5 Imaging
4.1.5.1 Imaging Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.6 Others
4.1.6.1 Others Neurological Biomarkers Market, 2018-2030 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, by Application, 2018-2030 (USD Million)
5.1 Neurological Biomarkers Market: Application Movement Analysis
5.1.1 Alzheimer’s Disease
5.1.1.1 Alzheimer’s Disease Market, 2018-2030 (USD Million)
5.1.2 Parkinson’s Disease
5.1.2.1 Parkinson’s Disease Market, 2018-2030 (USD Million)
5.1.3 Multiple Sclerosis
5.1.3.1 Multiple Sclerosis Market, 2018-2030 (USD Million)
5.1.4 Autism Spectrum Disorder
5.1.4.1 Autism Spectrum Disorder Market, 2018-2030 (USD Million)
5.1.5 Others
5.1.5.1 Others Market, 2018-2030 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, by End Use, 2018-2030 (USD Million)
6.1 Neurological Biomarkers Market: End Use Movement Analysis
6.1.1 Research Organizations
6.1.1.1 Research Organizations Market, 2018-2030 (USD Million)
6.1.2 Pharma & Biotech Companies
6.1.2.1 Pharma & Biotech Companies Market, 2018-2030 (USD Million)
6.1.3 Clinical Diagnostics
6.1.3.1 Clinical Diagnostics Market, 2018-2030 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, by Region, 2018-2030 (USD Million)
7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Neurological Biomarkers Market Estimates and Forecast, 2018-2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario
7.2.4 Mexico
7.2.4.1 Mexico Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.4.2 Key Country Dynamics
7.2.4.3 Regulatory Framework
7.2.4.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.2 Uk
7.3.2.1 Uk Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Argentina
7.5.3.1 Argentina Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New Product Launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Abbott
8.4.1.1 Company Overview
8.4.1.2 Financial Performance
8.4.1.3 Product Benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 Johnson & Johnson Services, Inc.
8.4.2.1 Company Overview
8.4.2.2 Financial Performance
8.4.2.3 Product Benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Bio-Rad Laboratories, Inc.
8.4.3.1 Company Overview
8.4.3.2 Financial Performance
8.4.3.3 Product Benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Alseres Pharmaceuticals, Inc.
8.4.4.1 Company Overview
8.4.4.2 Product Benchmarking
8.4.5 Banyan Biomarkers, Inc.
8.4.5.1 Company Overview
8.4.5.2 Product Benchmarking
8.4.5.3 Strategic Initiatives
8.4.6 Rules-Based Medicine
8.4.6.1 Company Overview
8.4.6.2 Financial Performance
8.4.6.3 Product Benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Thermo Fisher Scientific, Inc.
8.4.7.1 Company Overview
8.4.7.2 Financial Performance
8.4.7.3 Product Benchmarking
8.4.7.4 Strategic Initiatives
8.4.8 Diagenic Asa
8.4.8.1 Company Overview
8.4.8.2 Product Benchmarking
8.4.9 Merck & Co., Inc.
8.4.9.1 Company Overview
8.4.9.2 Financial Performance
8.4.9.3 Product Benchmarking
8.4.9.4 Strategic Initiatives
8.4.10 Quanterix
8.4.10.1 Company Overview
8.4.10.2 Product Benchmarking
8.4.10.3 Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 3 North America neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 4 North America neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 5 U.S. neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 6 U.S. neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 7 U.S. neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 8 Canada neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 9 Canada neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 10 Canada neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 11 Mexico neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 12 Mexico neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 13 Mexico neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 14 Europe neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 15 Europe neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 16 Europe neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 17 UK neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 18 UK neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 19 UK neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 20 Germany neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 21 Germany neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 22 Germany neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 23 France neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 24 France neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 25 France neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 26 Italy neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 27 Italy neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 28 Italy neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 29 Spain neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 30 Spain neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 31 Spain neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 32 Denmark neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 33 Denmark neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 34 Denmark neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 35 Sweden neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 36 Sweden neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 37 Sweden neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 38 Norway neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 39 Norway neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 40 Norway neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 41 Asia Pacific neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 42 Asia Pacific neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 43 Asia Pacific neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 44 Japan neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 45 Japan neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 46 Japan neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 47 China neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 48 China neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 49 China neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 50 India neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 51 India neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 52 India neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 53 South Korea neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 54 South Korea neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 55 South Korea neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 56 Australia neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 57 Australia neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 58 Australia neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 59 Thailand neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 60 Thailand neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 61 Thailand neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 62 Latin America neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 63 Latin America neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 64 Latin America neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 65 Brazil neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 66 Brazil neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 67 Brazil neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 68 Argentina neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 69 Argentina neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 70 Argentina neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 71 MEA neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 72 MEA neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 73 MEA neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 74 South Africa neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 75 South Africa neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 76 South Africa neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 77 Saudi Arabia neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 78 Saudi Arabia neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 80 UAE neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 81 UAE neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 82 UAE neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 83 Kuwait neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 84 Kuwait neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 85 Kuwait neurological biomarkers market, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Neurological biomarkers market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Market snapshot
Figure 10 Segment snapshot (Type and application)
Figure 11 Segment snapshot (End-use)
Figure 12 Competitive landscape snapshot
Figure 13 Biomarkers market value, 2022 (USD Million)
Figure 14 Neurological biomarkers market dynamics
Figure 15 Prevalence of Alzheimer's disease by age group, 2024
Figure 16 Neurological biomarkers market: PORTER’s analysis
Figure 17 Neurological biomarkers market: PESTLE analysis
Figure 18 Neurological biomarkers market: Type outlook and key takeaways
Figure 19 Neurological biomarkers market: Type movement analysis
Figure 20 Genomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Proteomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Metabolomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Imaging market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Other neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Neurological biomarkers market: Application outlook and key takeaways
Figure 26 Neurological biomarkers market: Application movement analysis
Figure 27 Alzheimer’s disease market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Parkinson’s disease market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Multiple sclerosis market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Autism spectrum disorder market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Neurological biomarkers market: End-use outlook and key takeaways
Figure 33 Neurological biomarkers market: End-use movement analysis
Figure 34 Research Organizations market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Pharma & Biotech Companies market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Clinical Diagnostics market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Neurological biomarkers market revenue, by region, 2022 & 2030 (USD Million)
Figure 38 Regional marketplace: Key takeaways
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Key country dynamics
Figure 42 U.S. neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Target disease prevalence
Figure 44 Key country dynamics
Figure 45 Canada neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Target disease prevalence
Figure 47 Europe neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 UK neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Key country dynamics
Figure 51 Germany neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 52 Target disease prevalence
Figure 53 Key country dynamics
Figure 54 France neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Italy neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 57 Key country dynamics
Figure 58 Spain neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 59 Key country dynamics
Figure 60 Denmark neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Sweden neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 63 Key country dynamics
Figure 64 Norway neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 65 Target disease prevalence
Figure 66 Rest of Europe market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Asia Pacific market estimates and forecast, 2018-2030 (USD Million)
Figure 68 Key country dynamics
Figure 69 Japan neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 70 Target disease prevalence
Figure 71 Key country dynamics
Figure 72 China neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 India neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 75 Target disease prevalence
Figure 76 Key country dynamics
Figure 77 Australia neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 78 Key country dynamics
Figure 79 Thailand neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 80 Key country dynamics
Figure 81 South Korea neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 82 Rest of Asia Pacific market estimates and forecast, 2018-2030 (USD Million)
Figure 83 Latin America neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Brazil neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Key country dynamics
Figure 87 Mexico neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 88 Key country dynamics
Figure 89 Argentina neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 MEA neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 92 Key country dynamics
Figure 93 South Africa neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 94 Target disease prevalence
Figure 95 Key country dynamics
Figure 96 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 Target disease prevalence
Figure 98 Key country dynamics
Figure 99 UAE neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 100 Target disease prevalence
Figure 101 Key country dynamics
Figure 102 Kuwait neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 103 Target disease prevalence
Figure 104 Key payors in Kuwait
Figure 105 Rest of MEA neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 106 Key company categorization
Figure 107 Company market positioning
Figure 108 Company market share analysis, 2022
Figure 109 Strategic framework

Companies Mentioned

The companies profiled in this Neurological Biomarkers market report include:
  • Abbott
  • Thermo Fisher Scientific, Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • Johnson & Johnson Services, Inc.
  • DiaGenic ASA
  • BANYAN BIOMARKERS, INC.
  • Quanterix
  • Alseres Pharmaceuticals, Inc.
  • Rules-Based Medicine
  • C2N Diagnostics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.75 Billion
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Neurological Biomarkers Market by Type, Application, End-user - Global Forecast 2025-2030 - Product Image

Neurological Biomarkers Market by Type, Application, End-user - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2024-2032 - Product Image

Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Neurological Biomarkers - Global Strategic Business Report - Product Image

Neurological Biomarkers - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Neurological Biomarkers for Alzheimer's and Parkinson's Diseases - Global Strategic Business Report - Product Image

Neurological Biomarkers for Alzheimer's and Parkinson's Diseases - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.